Allan S G, Gregor A, Cornbleet M A, Leonard R C, Smyth J F, Grant I W, Crompton G K
Cancer Chemother Pharmacol. 1984;13(2):106-8. doi: 10.1007/BF00257124.
Forty-three previously untreated patients, all of whom had poor-prognosis small cell lung cancer and/or were greater than 65 years old, received treatment with vindesine and VP16-213. Thirteen patients had limited disease and 30 extensive disease. Response rates (CR + PR) of 86% (CR 29%) and 66% (CR 17%) were seen in patients with limited and extensive disease, respectively. Time to relapse was short in those responding (4-4.5 months), and most responders required additional treatments. The overall toxicity was minimal and patient compliance was high. This combination is useful for the palliative treatment of small cell lung cancer when aggressive chemotherapy is inappropriate.
43例既往未接受过治疗的患者，均患有预后不良的小细胞肺癌和/或年龄大于65岁，接受了长春地辛和依托泊苷（VP16 - 213）治疗。13例患者为局限性疾病，30例为广泛性疾病。局限性疾病和广泛性疾病患者的缓解率（完全缓解+部分缓解）分别为86%（完全缓解29%）和66%（完全缓解17%）。缓解患者的复发时间较短（4 - 4.5个月），且大多数缓解者需要额外治疗。总体毒性极小，患者依从性高。当不适合进行积极化疗时，这种联合方案对小细胞肺癌的姑息治疗有用。
